Microbot Medical confirms no business disruption amid Middle East events, progresses LIBERTY commercial launch

Microbot Medical Inc.

No business disruption in USA or Israel; all personnel operational, lead manufacturing partner fully functional.
LIBERTY system received FDA clearance; limited market release began late 2025; full market release at SIR April 2026.
Hired additional U.S. sales representatives and a Director of Health Economics and Outcomes Research (HEOR) for commercial expansion.
Sufficient U.S. inventory maintained; building additional stock via third-party logistics partner for anticipated demand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.